Severe aplastic anaemia

The PBS subsidises eltrombopag for patients with severe aplastic anaemia.

Please note: You’ll get an immediate assessment when you request PBS authorities online.

Patient eligibility

The Pharmaceutical Benefits Scheme (PBS) subsidises treatment with eltrombopag under the National Health Act 1953, section 100 for patients with severe aplastic anaemia.

Patients must be eligible for the PBS and meet the relevant restriction criteria.

The Schedule of Pharmaceutical Benefits on the PBS website outlines the restrictions for prescribing eltrombopag.

Section 100 arrangements

Eltrombopag

This item is only PBS-subsidised for non-admitted patients, day admitted patients, or patients on discharge who are attending:

  • an approved private hospital
  • a public hospital.

This item isn’t PBS-subsidised for public hospital in-patients. You must include the hospital name and provider number on the authority application form.

Authority applications

First line setting

Applying for first-line treatment

Applications for authority approval to prescribe PBS-subsidised eltrombopag as first-line treatment to treat severe aplastic anaemia can be made either in:

All written applications must include:

Applying for grandfather treatment

Applications for grandfather authority approval to prescribe PBS-subsidised eltrombopag as first-line treatment to treat severe aplastic anaemia can be made either in:

All written applications must include:

Second line setting

Applying for initial second-line treatment

Applications for initial authority approval to prescribe PBS-subsidised eltrombopag as second-line treatment to treat severe aplastic anaemia can be made either in:

All written applications must include:

Applying for continuing second-line treatment

Applications for continuing authority approval to prescribe PBS-subsidised eltrombopag as second-line treatment to treat severe aplastic anaemia can be made either:

More information

Call the PBS Complex Drugs Programs enquiry line for more information.

Page last updated: 17 June 2024.
QC 65886